TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a clinical-stage immuno-oncology company developing therapies intended to address resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is an innate immune agonist designed to make tumor cells appear bacterial and stimulate an immune response; the company began a… From the company’s description.
In fiscal 2025, TuHURA Biosciences, Inc. reported a net loss of $30.05M. Operations used $27.63M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TuHURA Biosciences, Inc. does
In the company’s own words
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a clinical-stage immuno-oncology company developing therapies intended to address resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is an innate immune agonist designed to make tumor cells appear bacterial and stimulate an immune response; the company began a Phase 3 trial in June 2025, evaluating it with pembrolizumab for advanced or metastatic Merkel cell carcinoma. TuHURA also develops TBS-2025, a monoclonal antibody that inhibits the VISTA immune checkpoint, with planned studies in relapsed or refractory acute myeloid leukemia characterized by NPM1 mutations. Its third technology program uses Delta Opioid Receptor inhibitors to develop bispecific, bifunctional antibody-drug conjugates targeting immunosuppressive myeloid-derived suppressor cells. The company’s programs span clinical and preclinical development; it does not describe reportable business segments. TuHURA acquired TBS-2025 through its June 2025 merger with Kineta and acquired intellectual property underlying its Delta Opioid Receptor technology in 2023.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- TAMPA, FL
- Fiscal year end
- December
- CIK
- 1498382
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TuHURA Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TuHURA Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TuHURA Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TuHURA Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TuHURA Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”